Loss of Antibody with anti-CD20 associated with poor COVID response

L

Bellinvia A, Aprea MG, Portaccio E, Pastò L, Razzolini L, Fonderico M, Addazio I, Betti M, Amato MP Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies. .Neurol Sci. 2022:1-12. doi: 10.1007/s10072-022-06287-2. Online ahead of print

Background: COVID-19 vaccination is highly recommended to multiple sclerosis (MS) patients. Little is known about the role of patients’ clinical and demographic characteristics in determining antibody response.

Methods: We evaluated safety and efficacy of anti-SARS-CoV-2 vaccines on 143 included MS patients. Then, we analyzed antibody titer in a subgroup, assessing clinical and demographic variables associated with protection and antibody titer.

Results: After completing the vaccination cycle, the rate of local adverse events was similar after the first and second dose. A higher proportion of systemic AEs was reported after the second dose (65.7% vs 24.5% after the first dose). Antibody response was evaluated in 97 patients. Higher EDSS (OR 0.6, 95% CI 0.4-0.9, p = 0.006) and treatment with antiCD20 (OR 0.02, 95% CI 0.003-0.098, p 0.001) were associated with a lower chance of having an efficacious response. Higher weight was associated with higher Ab titer (β = 15.2, 95% CI 2.8-27.6, p = 0.017), while treatment with antiCD20 with lower titers (β = – 1092.3, 95% CI – 1477.4 to – 702.2, p < 0.001). In patients treated with antiCD20, hypogammaglobulinemia (β – 543, 95% CI – 1047.6 to – 39.1, p = 0.036) and treatment duration (β – 182, 95% CI – 341.4 to – 24.3, p = 0.027) were associated with lower Ab titer.

Conclusion: Our study confirms that COVID-19 vaccination in MS patient is safe and effective in preventing symptomatic COVID-19 and should be recommended to all patients. Moreover, we suggest a possible role of hypogammaglobulinemia in reducing Ab response in patients treated with antiCD20 therapies.

About the author

MouseDoctor

2 comments

  • Hi, I’m Suebee and I been using, an anticd20 for over 3 yrs. [welcome subee]. I’m afraid to stop using because I think it helps me perform better. Using has also impacted my life in a bad way: I am afraid to go anywhere in public. Rather than stop using, I had local hospital shoot me up 4x with anti-SARS-CoV-2 over past couple of years. CDC guidelines says users like me shouldn’t be tested for antibodies. But Using makes me desperate, so I gave up all rts to all my medical information in exchange for 3 antibody tests in a govt funded clinical study. ( Sometimes users make deals that don’t work out.) I have zero antibodies. Time, however, can make data separate the wheat from the chaff. 2x I lived with Covid infected household members but did not catch. I think my using with multiple negative PCRs made me stand out (visible). You scientists of world will be happy to know I got really generous offer for 5 more blood drawn antibody tests in exchange for a quick survey! Maybe they read your post Mousedoctor??! Race, weight, number of household members, employment, and education level achieved, I answered all. White, a bit chubby still cute, 3-5, no but a bit overeducated. (favorite survey question, “please indicate extent to which you view the pandemic as having Either positive or negative impact on your life”. 🙃 ) All kidding aside, the survey Didnt ask about ANY mitigation techniques. Mask type and use, air filtration, do I have a pod of friends, eat alfresco, frequent public places, use of curbside or home delivery of goods, travel for fun or business, number of times I go to a gym or medical facility a month. Scientists can do better. Please do better. But don’t take my word for it see https://doi.org/10.2105%2FAJPH.2016.303416
    That concludes,
    “studies of greatest consequence will be those that ask questions designed to enable intelligent policymaking.”
    Or just listen to Yogi Berra
    “You can observe a lot just by watching.”

  • Ehrrr… So what was I to gleam from this? Anti CD20, less antibody (we know). More exposure over time, less antibody (we know) Less response if heavier with same dose (we know, I think), safe (sure, we know), Hypogammaglobulinemia is associated with antibody loss. (Well, I assume something is happening to reduce B cells.) Effective? Where’s that? I’m not a med doc, so I assume there is a point here I have missed.

By MouseDoctor

Translate

Categories

Recent Posts

Recent Comments

Archives